全文获取类型
收费全文 | 134501篇 |
免费 | 45322篇 |
国内免费 | 495篇 |
专业分类
耳鼻咽喉 | 1901篇 |
儿科学 | 5539篇 |
妇产科学 | 1174篇 |
基础医学 | 25392篇 |
口腔科学 | 7785篇 |
临床医学 | 16817篇 |
内科学 | 29943篇 |
皮肤病学 | 4804篇 |
神经病学 | 19665篇 |
特种医学 | 6142篇 |
外国民族医学 | 4篇 |
外科学 | 17208篇 |
综合类 | 2035篇 |
现状与发展 | 1篇 |
一般理论 | 8篇 |
预防医学 | 9967篇 |
眼科学 | 1583篇 |
药学 | 12702篇 |
9篇 | |
中国医学 | 3470篇 |
肿瘤学 | 14169篇 |
出版年
2024年 | 119篇 |
2023年 | 751篇 |
2022年 | 1065篇 |
2021年 | 3006篇 |
2020年 | 7184篇 |
2019年 | 12554篇 |
2018年 | 12054篇 |
2017年 | 13133篇 |
2016年 | 12119篇 |
2015年 | 11920篇 |
2014年 | 12637篇 |
2013年 | 13412篇 |
2012年 | 11511篇 |
2011年 | 11370篇 |
2010年 | 9857篇 |
2009年 | 6382篇 |
2008年 | 6994篇 |
2007年 | 5364篇 |
2006年 | 5109篇 |
2005年 | 4801篇 |
2004年 | 4521篇 |
2003年 | 4029篇 |
2002年 | 3768篇 |
2001年 | 2856篇 |
2000年 | 1640篇 |
1999年 | 493篇 |
1998年 | 233篇 |
1997年 | 183篇 |
1996年 | 167篇 |
1995年 | 128篇 |
1994年 | 134篇 |
1993年 | 83篇 |
1992年 | 89篇 |
1991年 | 83篇 |
1990年 | 78篇 |
1989年 | 65篇 |
1988年 | 53篇 |
1987年 | 45篇 |
1986年 | 40篇 |
1985年 | 53篇 |
1984年 | 45篇 |
1983年 | 33篇 |
1982年 | 19篇 |
1981年 | 28篇 |
1980年 | 25篇 |
1979年 | 21篇 |
1978年 | 12篇 |
1977年 | 11篇 |
1976年 | 10篇 |
1975年 | 12篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
1.
2.
《Vaccine》2022,40(27):3721-3726
We initiated a randomized, placebo-controlled, phase 1/2 trial to evaluate the safety and immunogenicity of the S-268019-b recombinant protein vaccine, scheduled as 2 intramuscular injections given 21 days apart, in 60 randomized healthy Japanese adults. We evaluated 2 regimens of the S-910823 antigen (5 μg [n = 24] and 10 μg [n = 24]) with an oil-in-water emulsion formulation and compared against placebo (n = 12). Reactogenicity was mild in most participants. No serious adverse events were noted. For both regimens, vaccination resulted in robust IgG and neutralizing antibody production at days 36 and 50 and predominant T-helper 1-mediated immune reaction, as evident through antigen-specific polyfunctional CD4+ T-cell responses with IFN-γ, IL-2, and IL-4 production on spike protein peptides stimulation. Based on the interim analysis, the S-268019-b vaccine is safe, produces neutralizing antibodies titer comparable with that in convalescent serum from COVID-19-recovered patients. However, further evaluation of the vaccine in a large clinical trial is warranted. 相似文献
3.
4.
《Vaccine》2021,39(42):6333-6339
Px563L is a next-generation anthrax vaccine candidate consisting of a protein subunit, mutant recombinant protective antigen SNKE167-ΔFF-315-E308D (mrPA), and liposome-embedded monophosphoryl lipid A (MPLA) adjuvant. Px563L has the potential to deliver an improved safety and immunogenicity profile relative to the currently licensed vaccine, which is produced from filtered B. anthracis culture supernatants.We conducted a Phase 1, double–blind, placebo–controlled, dose–escalation study in 54 healthy subjects to evaluate Px563L at 3 dose levels of mrPA (10, 50, and 80 mcg). For each dose level, 18 subjects were randomized in an 8:8:2 ratio to Px563L (mrPA with adjuvant), RPA563 (mrPA only) or placebo (saline). Each subject received an intramuscular (IM) injection on Day 0 and Day 28. Primary safety and immunogenicity analysis was conducted after all subjects completed the Day 70 visit, a duration deemed clinically relevant for post-exposure prophylaxis. Long-term safety was assessed through Day 393.Vaccinations with Px563L at all dose levels were well-tolerated. There were no serious adverse events or adverse events (AE) leading to early withdrawal. In all treatment groups, most AEs were due to injection site reactions, and all AEs at the 10 and 50 mcg dose levels were mild. For the primary immunogenicity endpoint (protective toxin neutralizing antibody 50% neutralization factor [TNA NF50]), titers started to increase significantly after the second administration of Px563L, from Day 35 through Day 70, with the geometric mean and lower bound of the 95% confidence interval exceeding 0.56, a threshold correlating with significant survival in animal models of anthrax exposure.In conclusion, Px563L, administered as two IM doses 28 days apart, was well-tolerated and elicited a protective antibody response starting at seven days after the second vaccination. These findings support the continued development of Px563L in a two-dose regimen for anthrax post-exposure prophylaxis. ClinicalTrials.gov identifier NCT02655549. 相似文献
5.
Zongzhang Huang Qigu Yao Jianping Zhu Ying He Yanghao Chen Feng Wu Teng Hua 《Diagnostic and interventional imaging》2021,102(5):279-285
PurposeThe purpose of this study was to make a systematic review and meta-analysis to determine the stent diameter (8 mm vs. 10 mm) that conveys better safety and clinical efficacy for transjugular intrahepatic portosystemic shunt (TIPS).Materials and methodsFour databases were used to identify clinical trials published from inception until March 2020. Data were extracted to estimate and compare one-year and three-year overall survivals, hepatic encephalopathy, variceal rebleeding, and shunt dysfunction rates between patients with 8 mm covered stents and those with 10 mm covered stents.ResultsFive eligible studies were selected, which included 489 patients (316 men, 173 women). The 8 mm covered stent group had higher efficacy regarding one-year or three-year overall survival (odds ratio [OR], 2.88; P = 0.003) and (OR, 1.81; P = 0.04) and lower hepatic encephalopathy (OR, 0.69; P = 0.04) compared with 10 mm covered stent group. There were no significant differences in variceal rebleeding rate (OR 0.80; P = 0.67). However, shunt dysfunction was lower in 10 mm covered stent group (OR, 2.26; P = 0.003).ConclusionsOur results suggest that the use of 8 mm covered stents should be preferred to that of 10 mm covered stents for TIPS placement when portal pressure is frequently monitored. 相似文献
6.
7.
8.
9.
《Journal of vascular and interventional radiology : JVIR》2022,33(4):359-367.e8
PurposeTo review and to compare indirectly the outcomes of minimally invasive therapies for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.Materials and MethodsA literature search via Medline and Cochrane Central databases was completed for randomized control studies published between January 2000 to April 2020 for the following therapies: Rezum, Urolift, Aquablation, and prostatic artery embolization (PAE). Data on the following variables were included: International prostate symptom score (IPSS), maximum urinary flow rate, quality of life, and postvoid residual (PVR). Standard mean differences between treatments were compared through a meta-analysis using transurethral resection of the prostate (TURP) to assess differences in treatment effect.ResultsThere was no significant difference in outcomes between therapies for IPSS at the 3, 6, and 12-month follow ups. Although outcomes for Rezum were only available out to 3 months, there were no consistently significant differences in outcomes when comparing Aquablation versus PAE versus Rezum. TURP PVR was significantly better than Urolift at 3, 6, and 12 months. No significant differences in minor or major adverse events were noted.ConclusionAlthough significant differences in outcomes were limited, Aquablation and PAE were the most durable at 12 months. PAE has been well studied on multiple randomized control trials with minimal adverse events while Aquablation has limited high quality data and has been associated with bleeding-related complications. 相似文献
10.
目的 系统评价中药治疗哮喘-慢阻肺(ACO)的疗效与安全性。方法 全面检索PubMed、Cochrane Library、Web of Science、中国知网、万方、维普、中国医学文献数据库,纳入有关中医药治疗ACO的随机对照试验(RCT),运用Cochrane手册对纳入研究的方法学质量进行评估,采用Review Manager 5.3进行Meta分析。结果 共纳入32项RCT,包括2688例ACO患者,其中试验组1361例,对照组1327例。Meta分析结果显示,中医药可以显著改善ACO患者的中医证候疗效[RR=1.19,95% CI(1.13,1.25),P<0.00001]、CAT评分[MD=-3.62,95% CI(-4.37,-2.87),P<0.00001]、ACT评分[MD=3.42,95% CI(2.23,4.62),P<0.00001],、中医证候总积分[MD=-3.61,95% CI(-4.83,-2.39),P<0.00001]、FEV1[MD=0.59,95% CI(0.08,1.10),P=0.02]、FEV1%[MD=8.61,95% CI(5.20,12.1),P<0.00001]、FEV1/FVC[MD=6.52,95% CI(4.24,8.80),P<0.00001]、6 min步行实验[MD=41.18,95% CI(22.15,60.21),P<0.0001]、急性发作次数[MD=-2.46,95% CI(-3.62,-1.13),P<0.0001]。所有研究均未报道严重不良反应。结论 中药治疗ACO,可以显著提高临床疗效,改善患者的肺功能且具有较好安全性,但是需要更高质量、多样本、多中心的随机对照试验进一步确认。 相似文献